Literature DB >> 11017109

DC-SIGN-ICAM-2 interaction mediates dendritic cell trafficking.

T B Geijtenbeek1, D J Krooshoop, D A Bleijs, S J van Vliet, G C van Duijnhoven, V Grabovsky, R Alon, C G Figdor, Y van Kooyk.   

Abstract

Dendritic cells (DCs) are recruited from blood into tissues to patrol for foreign antigens. After antigen uptake and processing, DCs migrate to the secondary lymphoid organs to initiate immune responses. We now show that DC-SIGN, a DC-specific C-type lectin, supports tethering and rolling of DC-SIGN-positive cells on the vascular ligand ICAM-2 under shear flow, a prerequisite for emigration from blood. The DC-SIGN-ICAM-2 interaction regulates chemokine-induced transmigration of DCs across both resting and activated endothelium. Thus, DC-SIGN is central to the unusual trafficking capacity of DCs, further supported by the expression of DC-SIGN on precursors in blood and on immature and mature DCs in both peripheral and lymphoid tissues.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11017109     DOI: 10.1038/79815

Source DB:  PubMed          Journal:  Nat Immunol        ISSN: 1529-2908            Impact factor:   25.606


  139 in total

1.  Encephalitogenic lymphoblast recruitment to resting CNS microvasculature: a natural immunosurveillance mechanism?

Authors:  R Alon
Journal:  J Clin Invest       Date:  2001-08       Impact factor: 14.808

2.  Unique appearance of proliferating antigen-presenting cells expressing DC-SIGN (CD209) in the decidua of early human pregnancy.

Authors:  Ulrike Kämmerer; Andreas O Eggert; Michaela Kapp; Alexander D McLellan; Teunis B H Geijtenbeek; Johannes Dietl; Yvette van Kooyk; Eckhart Kämpgen
Journal:  Am J Pathol       Date:  2003-03       Impact factor: 4.307

3.  C-type lectins DC-SIGN and L-SIGN mediate cellular entry by Ebola virus in cis and in trans.

Authors:  Carmen P Alvarez; Fátima Lasala; Jaime Carrillo; Oscar Muñiz; Angel L Corbí; Rafael Delgado
Journal:  J Virol       Date:  2002-07       Impact factor: 5.103

4.  Inhibition of human immunodeficiency virus type 1 Env-mediated fusion by DC-SIGN.

Authors:  Cinzia Nobile; Arnaud Moris; Françoise Porrot; Nathalie Sol-Foulon; Olivier Schwartz
Journal:  J Virol       Date:  2003-05       Impact factor: 5.103

Review 5.  DC-SIGN: binding receptor for HCV?

Authors:  Zhi-Hua Feng; Quan-Chu Wang; Qing-He Nie; Zhan-Sheng Jia; Yong-Xin Zhou
Journal:  World J Gastroenterol       Date:  2004-04-01       Impact factor: 5.742

6.  HIV-1 exploits innate signaling by TLR8 and DC-SIGN for productive infection of dendritic cells.

Authors:  Sonja I Gringhuis; Michiel van der Vlist; Linda M van den Berg; Jeroen den Dunnen; Manja Litjens; Teunis B H Geijtenbeek
Journal:  Nat Immunol       Date:  2010-04-04       Impact factor: 25.606

7.  DC-SIGN and CLEC-2 mediate human immunodeficiency virus type 1 capture by platelets.

Authors:  Chawaree Chaipan; Elizabeth J Soilleux; Peter Simpson; Heike Hofmann; Thomas Gramberg; Andrea Marzi; Martina Geier; Elizabeth A Stewart; Jutta Eisemann; Alexander Steinkasserer; Katsue Suzuki-Inoue; Gemma L Fuller; Andrew C Pearce; Steve P Watson; James A Hoxie; Frederic Baribaud; Stefan Pöhlmann
Journal:  J Virol       Date:  2006-09       Impact factor: 5.103

8.  Long-term productive human immunodeficiency virus infection of CD1a-sorted myeloid dendritic cells.

Authors:  Sergei Popov; Agnès-Laurence Chenine; Andreas Gruber; Pei-Lin Li; Ruth M Ruprecht
Journal:  J Virol       Date:  2005-01       Impact factor: 5.103

9.  Evaluation of the role of the endocytic receptor L-SIGN for cytoadhesion of Plasmodium falciparum-infected erythrocytes.

Authors:  Nicola K Viebig; Katherine T Andrews; Yvette van Kooyk; Michael Lanzer; Percy A Knolle
Journal:  Parasitol Res       Date:  2005-05-04       Impact factor: 2.289

10.  DC-SIGN facilitates fusion of dendritic cells with human T-cell leukemia virus type 1-infected cells.

Authors:  Pierre-Emmanuel Ceccaldi; Frédéric Delebecque; Marie-Christine Prevost; Arnaud Moris; Jean-Pierre Abastado; Antoine Gessain; Olivier Schwartz; Simona Ozden
Journal:  J Virol       Date:  2006-05       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.